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Abstract
Histopathological evidence supports the idea that the emergence of phenotypic hetero-
geneity and resistance to cytotoxic drugs can be considered as a process of adaptation, or
evolution, in tumor cell populations. In this framework, can we explain intra-tumor hetero-
geneity in terms of cell adaptation to local conditions? How do anti-cancer therapies affect
the outcome of cell competition for nutrients within solid tumors? Can we overcome the
emergence of resistance and favor the eradication of cancer cells by using combination thera-
pies? Bearing these questions in mind, we develop a model describing cell dynamics inside a
tumor spheroid under the effects of cytotoxic and cytostatic drugs. Cancer cells are assumed
to be structured as a population by two real variables standing for space position and the
expression level of a cytotoxic resistant phenotype. The model takes explicitly into account
the dynamics of resources and anti-cancer drugs as well as their interactions with the cell
population under treatment. We analyze the effects of space structure and combination ther-
apies on phenotypic heterogeneity and chemotherapeutic resistance. Furthermore, we study
the efficacy of combined therapy protocols based on constant infusion and/or bang-bang
delivery of cytotoxic and cytostatic drugs.
1 Introduction
Cytotoxic drugs are the most widely used weapon in the fight against cancer. However, these
drugs usually cause unwanted toxic side effects in the patients’ organisms, since they are seldom
specific toward tumor cells. Furthermore, they tend to kill strongly proliferative clones, usually
considered as made of the most drug-sensitive cells [20], thus favoring the emergence of resistance
to therapies [7, 8, 12, 26]. These are the two major obstacles - toxic side effects and emergence
of resistant clones - encountered in the clinic when making use of cytotoxic agents in treating
tumors. This situation calls for therapy optimization, that is, identification of drug doses and
design of optimal delivery schedules in multi-drug combinations, allowing for an effective control
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of cancer growth, consisting of a reduction in the probability of resistance emergence together
with the minimization of side effects on healthy tissues.
As regards multi-drug combinations, a trend in the modern clinic of cancers leads to combining
cytotoxic drugs, (i.e., DNA damaging agents, antimetabolites, etc.) that lead hit cells to their
death, together with cytostatic ones, defined as drugs that are not intended, at least at non
massive doses, to harm cells, but rather to slow down proliferation (by blocking growth factor
receptors or downstream intracellular pathways involved in proliferation, e.g., tyrosine kinase
inhibitors). In fact, cytostatic drugs have lower toxicity for healthy cells and allow the survival of
a small number of cancer clones, that are assumed to be sensitive to cytotoxic agents [24, 28, 29].
Since sensitive cells can hamper the growth of the resistant ones through competition for space
and resources, this mode of therapy combination allows to attain the twofold goal of reducing
toxicity and holding in check the multiplication of resistant clones, thus establishing as a practical
therapeutic strategy the principle at the basis of adaptive therapies: maintaining the persistence
of sensitive tumor cells, which are more fit than the resistant ones in low drug pressure conditions,
instead of pursuing the often elusive goal of eradicating the tumor as a whole [3, 4].
As far as drug delivery schedules are concerned, it has been suggested that infusion protocols
based on bang-bang control (i.e., those protocols in which drug delivery is alternatively switched
on and off over time) can allow an effective control of tumor size [14]. We will focus here on
the case where tumor cells are exposed to square-wave infusions of cytotoxic and/or cytostatic
drugs at constant concentrations and with different durations/maximal doses.
Histopathological evidence supports the idea that the emergence of resistance to anti-cancer
therapies can be considered as a process of Darwinian micro-evolution in tumor cell populations
[5, 18]. In fact, malignant clones with heterogeneous genetic/epigenetic expression leading to
different phenotypes (e.g., epithelial vs. mesenchymal, with the same genetic material [30]) can
be seen as competing for space and resources (i.e., oxygen, glucose or other nutrients) within
the environment defined by the surrounding tissues, together with the selective pressure exerted
by therapeutic actions.
According to this view, focusing here on a cancer cell population as reference system (i.e.,
not taking into account unwanted toxicity to healthy cells, which is a theme we had explored in
a previous paper [15]), we propose a structured population model describing cellular dynamics
under the effects of cytotoxic and/or cytostatic drugs. The model we design includes birth
and death processes involving cancer cells. Furthermore, it also takes explicitly into account the
dynamics of resources and anti-cancer drugs as well as their interactions with the cell population
under treatment.
Tumor cells are assumed to be organized in a radially symmetric spheroid and to be structured
as a population by two non-negative real variables x ∈ [0; 1] and r ∈ [0; 1] standing, respectively,
for the normalized expression level of a cytotoxic resistant phenotype and for the normalized
distance from the center of the spheroid. This implies that, unlike in probabilistic or individual
based models, we do not consider that a cell is necessarily either totally sensitive or totally resis-
tant to a given drug; we rather introduce a continuous structuring variable describing resistance
between 0 (highly sensitive) and 1 (highly resistant).
It should be noted that, compared with the model proposed in [15], the present one is able
to mimic the simultaneous selection of several traits (i.e., the rise of phenotypic polymorphism)
within the cancer cell population, which provides the basis for intra-tumor heterogeneity. The
additional spatial structure variable r, together with the diffusion along the r-axis of nutrients
and therapeutic drugs, are the key ingredients of this model that make possible the emergence of
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such a heterogeneous scenario, which is close to the ones observed in biological experimentations
[1, 5, 25]. An alternative way to obtain the emergence of intra-tumor heterogeneity has been
namely proposed in [13], by considering sufficiently large mutations in the models from [15].
At this stage, let us stress that both structure variables, x and r, have a well defined biological
meaning, so that they can be evaluated by means of laboratory experiments. In particular, a
cell resistance level can be measured either by the average molecular cell concentration, or,
better, activity, of ABC transporters, that are known to be associated with resistance to the
drug [22, 26], or by the minimal dose of each drug under consideration to kill a given percentage
of the cell population [32].
Let us furthermore mention that the derivation of models able to include both evolution and
spatial dynamics, as the one here presented, is a key step toward a better comprehension of
those mechanisms that underly the evolution of ecological systems in general. These models can
pave the way to interesting mathematical questions; see for instance [19] and references therein.
The paper is organized as follows. In Section 2, we describe the mathematical model, the
related underlying assumptions and the general setup for numerical simulations. Section 3
is devoted to study cell environmental adaptation in the framework of this model, i.e., how
tumor cells adapt to the surrounding environment defined by nutrients and anti-cancer drugs.
In particular, the evolution of phenotypic heterogeneity and chemotherapeutic resistance are
analyzed in presence of cytotoxic and cytostatic drugs. With the aim of supporting the design
of optimal therapeutic strategies, in Section 4 we test the efficacy of therapeutic protocols
based on constant infusion and/or bang-bang delivery (i.e., infusion schedules relying on bang-
bang control) of cytotoxic drugs, cytostatic drugs or combinations of cytotoxic and cytostatic
drugs. Conclusions are drawn in Section 5, which provides also some ideas about future research
perspectives.
2 A structured population model for a tumor cell spheroid ex-
posed to anti-cancer drugs
We first present the mathematical model and the related underlying assumptions. In more
detail, Subsection 2.1 describes the strategies developed to translate into mathematical terms
the phenomena under consideration and presents the model, while Subsection 2.2 summarizes
the general setup for numerical simulations of the Cauchy problem defined by endowing the
model with biologically consistent initial and boundary conditions.
2.1 Model and underlying assumptions
The reference system is defined by a population of tumor cells exposed to cytotoxic and cytostatic
drugs. As previously noted, the cell population is assumed to be organized in a radially sym-
metric spheroid and to be structured by two non-negative real variables x ∈ [0, 1] and r ∈ [0, 1].
The former represents the normalized expression level of a cytotoxic resistant phenotype (i.e.,
roughly speaking, the level of resistance to cytotoxic agents), while the latter stands for the
distance of cells from the center of the spheroid, whose radius is assumed to be normalized in
order to have unitary length.
The density of cancer cells is modeled by function n(t, r, x) ≥ 0, so that local and total density
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at time t ∈ [0,∞) are computed, respectively, as
%(t, r) =
∫ 1
0
n(t, r, x)dx, %T (t) =
∫ 1
0
%(t, r)dr,
while the average level of resistance χ(t) expressed by the whole cell population and the related
variance σ2(t) can be evaluated as
χ(t) =
∫ 1
0
∫ 1
0
x
n(t, r, x)
%T (t)
dxdr, σ2(t) =
∫ 1
0
∫ 1
0
x2
n(t, r, x)
%T (t)
dxdr − χ(t)2.
In the mathematical framework at hand, function σ2(t) provides a possible measure for intra-
tumor phenotypic heterogeneity at time t. Function s(t, r) ≥ 0 identifies the concentration of
nutrients available to cells (oxygen and glucose, since in this setting we do not consider the
glycolytic phenotype, i.e., we do not distinguish between these two nutrients). The densities of
cytotoxic and cytostatic drugs are described, respectively, by c1(t, r) ≥ 0 and c2(t, r) ≥ 0.
We assume that the evolution of functions n, s, c1 and c2 is ruled by the following set of
equations
∂tn(t, r, x) =
[
p(x)
1 + µ2c2(t, r)
s(t, r)− d(x)%(t, r)− µ1(x)c1(t, r)
]
n(t, r, x), (2.1)
−σs∆s(t, r) +
[
γs +
∫ 1
0
p(x)n(t, r, x)dx
]
s(t, r) = 0, (2.2)
−σc∆c1(t, r) +
[
γc +
∫ 1
0
µ1(x)n(t, r, x)dx
]
c1(t, r) = 0, (2.3)
−σc∆c2(t, r) +
[
γc + µ2
∫ 1
0
n(t, r, x)dx
]
c2(t, r) = 0, (2.4)
with zero Neumann conditions at r = 0 coming from radial symmetry and Dirichlet boundary
conditions at r = 1
s(t, r = 1) = s1, ∂rs(t, r = 0) = 0, c1,2(t, r = 1) = C1,2(t), ∂rc1,2(t, r = 0) = 0, (2.5)
where:
• Function p(x) is the proliferation rate of cells expressing resistance level x due to the con-
sumption of resources. Factor
1
1 + µ2c2(t, r)
mimics the effects of cytostatic drugs, which act by slowing down cellular proliferation, rather
than by killing cells. Parameter µ2 models the average uptake rate of these drugs.
• Function d(x) models the death rate of cells with resistance level x due to the competition for
space and resources with the other cells.
• Function µ1(x) denotes the destruction rate of cells due to the consumption of cytotoxic drugs,
whose effects are here summed up directly on mortality (i.e., in this simple setting, not involving
the cell division cycle, we do not consider drug effects on cell cycle phase transitions [11]).
• Parameters σs and σc model, respectively, the diffusion constants of nutrients and cyto-
toxic/cytostatic drugs.
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• Parameters γs and γc represent the decay rate of nutrients and cytotoxic/cytostatic drugs,
respectively.
Model (2.1) can be recast in the equivalent form
∂tn(t, r, x) = R
(
x, %(t, r), c1,2(t, r), s(t, r)
)
n(t, r, x),
in order to highlight the role played by the net growth rate of cancer cells, which is described
by
R
(
x, %(t, r), c1,2(t, r), s(t, r)
)
:= p(x)1 + µ2c2(t, r)
s(t, r)− d(x)%(t, r)− µ1(x)c1(t, r).
The following considerations and hypothesis are assumed to hold:
• With the aim of translating into mathematical terms the idea that expressing cytotoxic re-
sistant phenotype implies resource reallocation (i.e., redistribution of energetic resources from
proliferation-oriented tasks toward development and maintenance of drug resistance mechanisms,
such as higher expression or activity of ABC transporters [22, 26] in individual cells), we assume
p to be decreasing
p(·) > 0, p′(·) < 0. (2.6)
• In order to include the fact that mutations conferring resistance to cytotoxic therapies may
also provide cells with stronger competitive abilities, function d is assumed to be non-increasing
d(·) > 0, d′(·) ≤ 0. (2.7)
• The effects of resistance to cytotoxic therapies are modeled by assuming function µ1 to be
non-increasing
µ1(·) > 0, µ′1(·) ≤ 0. (2.8)
2.2 Setup for numerical simulations
Numerical simulations are performed in Matlab making use of an implicit-explicit finite differ-
ence scheme combined with a shooting method with 200×200 points on the square [0, 1]× [0, 1].
Interval [0, T ] is selected as time domain, with T = 700 in Section 3 and T = 3000 in Section 4
(time step dt = 0.1).
We choose the initial and boundary conditions to be
n(t = 0, r, x) = n0(r, x) := C0 exp(−(x− 0.5)2/0.005), (2.9)
s(t, r = 1) = s1 := 0.3, c1,2(t, r = 1) = C1,2(t), (2.10)
where C1,2(t) are positive real functions, which model the infusion rates of cytotoxic/cytostatic
drugs and are defined case by case according to the situation under investigation in each sub-
section of Section 3 and Section 4. Choice (2.9) mimics a biological scenario where most of the
cells are characterized by the same intermediate level of resistance to therapies at the beginning
of observations (i.e., the cell population is almost monomorphic). The normalization constant
C0 is set equal to 0.1.
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In accordance with assumptions (2.6)-(2.8), the other functions and parameters of the model
are set as follows along all simulations:
p(x) := 0.1 + (1− x), d(x) := 3 + 1.5(1− x)2, µ1(x) := 0.01 + (1− x)2, (2.11)
and
µ2 := 10, σs = σc := 0.2, γs = γc := 1. (2.12)
The above polynomial functions and the related parameters are chosen to be simple and offering
clear illustrations of the generic properties set in (2.6)-(2.8).
3 Study of cell environmental adaptation and phenotypic het-
erogeneity
For the model described in the previous section, we now study how tumor cells adapt to the sur-
rounding environment defined by nutrients and anti-cancer drugs. Subsection 3.1 deals with cell
dynamics without therapies, while in Subsection 3.2 we analyze the effects of constant infusions
of cytotoxic and cytostatic drugs. Considerations about the evolution of intra-tumor hetero-
geneity are drawn in Subsection 3.3, and a qualitative mathematical justification for phenotypic
selection is provided by Subsection 3.4.
3.1 Cell dynamics without therapies
We begin our study by analyzing the dynamics of cancer cells without therapies (i.e., C1,2(t) := 0
for any t ∈ [0, T ]). The obtained results are summarized by the right panel in Fig. 1, which
shows how, in the absence of therapeutic agents, cells characterized by lower resistance levels
and thus, using assumption (2.6), by stronger proliferative potentials, are selected. At each
position r, a different trait X(T, r) is favored (i.e., for each value of r, n(T, r, x) concentrates
in a different point X(T, r)). This is due to the fact that the density of resources varies along
the radius of the spheroid (i.e., s(T, r) attains different values at any r, see solid line in the left
panel of Fig. 2). In other words, different densities of available nutrients imply the selection
of different levels of abilities to get resources and this provides the basis for the emergence of
polymorphism within the tumor cell population at hand.
3.2 Cell dynamics under infusion of cytotoxic or cytostatic drugs
At first, we consider the effects that constant infusions of cytotoxic drugs induce on cell dynamics,
i.e., we run simulations setting C1(t) := 1 and C2(t) := 0 for any t ∈ [0, T ]. The right panel in
Fig. 3 highlights how cytotoxic drugs promote a selective sweep toward resistant phenotypes. A
polymorphic scenario arises at the end of simulations also in this case; in fact, a different level of
resistance X(T, r) is selected at any level within the spheroid (i.e., for each value of r, n(T, r, x)
concentrates in a different point X(T, r)). By analogy with the case without therapies, this is
due to the fact that the concentrations of nutrients and cytotoxic drugs vary along the radius
of the spheroid (i.e., s(T, r) and c1(T, r) attain different values for different values of r, see solid
and dashed lines in the center panel in Fig. 2).
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Figure 1: (Cell dynamics without therapies) Plots of the average resistance trait distribu-
tion
∫ 1
0
n(T, r, x)dr/%T (T ) (left panel) and the phenotype distribution along the tumor radius
n(T, r, x)/%(T, r) (right panel) for C1,2(t) := 0. For each r value, the n(T, r, x) function concen-
trates in a different point X(T, r). Cells characterized by a low expression level of resistance to
cytotoxic therapies and by a strong proliferative potential are selected, and this is particularly
obvious at the rim of the spheroid (r = 1), where nutrients abound.
0 0.5 10
0.05
0.1
0.15
0.2
0.25
0.3
0.35
s(t,r), c1(t,r) and c2(t,r) at t=T
r
0 0.5 10
0.2
0.4
0.6
0.8
1
1.2
s(t,r), c1(t,r) and c2(t,r) at t=T
r
0 0.5 10
0.2
0.4
0.6
0.8
1
1.2
s(t,r), c1(t,r) and c2(t,r) at t=T
r
Figure 2: (Distributions of resources and drugs) Plot of s(T, r) (solid lines), c1(T, r)
(dashed lines) and c2(T, r) (dotted lines) for C1,2(t) := 0 (left panel), C1(t) := 1, C2(t) := 0
(center panel) and C1(t) := 0, C2(t) := 1 (right panel).
In order to study how cancer cells respond to the on-off switch of cytotoxic drug infusion, we
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Figure 3: (Cell dynamics under constant infusion of cytotoxic drugs) Plots of the
average resistance trait distribution
∫ 1
0
n(T, r, x)dr/%T (T ) (left panel) and the phenotype distri-
bution along the tumor radius n(T, r, x)/%(T, r) (right panel) for C1(t) := 1 and C2(t) := 0. For
each value of r, function n(T, r, x) concentrates in a different point X(T, r). Cells characterized
by high resistance levels are selected. As in the case without drugs, such evolution is particularly
obvious at the rim of the spheroid (r = 1), where drugs abound.
develop simulations setting
C1(t) :=
{
1, if t ∈ [0, T ]
0, if t ∈ (T, 2T ], (3.1)
and keeping C2(t) := 0 for any t ∈ [0, 2T ]. The above definition mimics a biological scenario
where cytotoxic drugs are delivered in the time interval [0, T ] only. Fig. 4 highlights the selection
of higher levels of resistance during the infusion of cytotoxic drugs, i.e., in the [0, T ] time interval,
and higher level of proliferative potential in the absence of cytotoxic drugs, i.e., on the (T, 2T ]
time interval. In fact, when the infusion of cytotoxic drugs is stopped, more proliferative, and
thus less resistant, cancer clones are favored [3, 4]. The switch from the selection for resistance
to proliferative potential occurs in a progressive and continuous way, rather than through jumps
in the distribution over the traits (see the right panel in Fig. 4).
We subsequently analyze the dynamics of cancer cells under the effects of constant infusion
of cytostatic drugs, i.e., we run simulations setting C1(t) := 0 and C2(t) := 1 for any t ∈ [0, T ].
The right panel in Fig. 5 shows how the cell distribution at the end of simulations is still close
to the initial one, that is, cytostatic drugs tend to slow down the evolution of cancer cells and
do not favor the emergence of resistance.
The results presented in this subsection lead us to conclude that phenotypic heterogeneity within
solid tumor aggregates might come from cell adaptation to local conditions. Cells characterized
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Figure 4: (On-off switch of cytotoxic drug infusion) Plots of
∫ 1
0
n(T, r, x)dr/%T (T ) (left-
top panel),
∫ 1
0
n(2T, r, x)dr/%T (2T ) (left-bottom panel), n(T, r, x)/%(T, r) (center-top panel),
n(2T, r, x)/%(2T, r) (center-bottom panel) and
∫ 1
0 n(t, r, x)dr for t ∈ [0, 2T ] (right panel), for
C1(t) defined by (3.1) and C2(t) := 0. The selection of higher levels of resistance occurs during
the infusion of cytotoxic drugs, i.e., in time interval [0, T ], while higher levels of proliferative
potential are selected in the absence of cytotoxic drugs, i.e., in time interval (T, 2T ].
Figure 5: (Cell dynamics under constant infusion of cytostatic drugs) Plots of the
average resistance trait distribution
∫ 1
0
n(T, r, x)dr/%T (T ) (left panel) and the phenotype dis-
tribution along the tumor radius n(T, r, x)/%(T, r) (right panel) for C1(t) := 0 and C2(t) := 1.
Cytostatic drugs slow down the evolution of cancer cells and do not favor the emergence of
resistance
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by different levels of proliferative potential and resistance to therapies are selected depending on
space position, in relation with the distributions of resources and anti-cancer drugs. Cytostatic
drugs tend to slow down tumor evolution, while cytotoxic drugs favor the selection of highly
resistant cancer clones.
3.3 Considerations about intra-tumor heterogeneity
A comparison between the results illustrated in the left panels in Fig. 1, Fig. 3 and Fig. 5 lead us
to conclude that intra-tumor heterogeneity is reduced under the effects of cytotoxic drugs. The
same idea is also supported by the results presented in Fig. 6, which highlight how these drugs
increase the average level of resistance expressed by the whole cell population χ(t) over time,
while the related variance σ2(t) decreases. In the framework of our model, this is in agreement
with the Gause competitive exclusion principle and it is consistent with experimental observa-
tions for the fact that cytotoxic drugs increase the selective pressure and favor highly resistant
cancer clones [8, 26].
In conclusion to this study of cell environmental adaptation, we observe that cytotoxic drugs
reduce intra-tumor heterogeneity of the resistance trait. This can be seen as an evolutionary
bottleneck in the cancer cell population [6, 25].
0 T/2 T
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
χ(t)
t
0 T/2 T
1
2.5
4
5.5
6.5 x 10
−3 σ2(t)
t
Figure 6: (Evolution of the average level of resistance and the related variance) Plot
of χ(t) (left panel) and σ2(t) (right panel) for C1,2(t) := 0 (solid lines), C1(t) := 1, C2(t) := 0
(dashed lines) and C1(t) := 0, C2(t) := 1 (dotted lines). Cytotoxic drugs increase the average
level of resistance χ(t) over time, while the related variance σ2(t) decreases. This may be
interpreted as a reduction of intra-tumor heterogeneity w.r.t. the resistance trait, due to the
delivery of the drugs inducing such resistance.
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3.4 A qualitative mathematical justification for phenotypic selection
From a mathematical standpoint, taking advantage of the considerations drawn in [16, 21], the
long term dynamics of X(t, r) can be formally characterized by solving the equation
lim
t→∞R
(
x = X(t, r), %(t, r), c1,2(t, r), s(t, r)
)
= R
(
x = X¯(r), %¯(r), c¯1,2(r), s¯(r)
)
= 0. (3.2)
In the case at hand, this is equivalent to finding the two roots of a second degree polynomial
and verifying whether they belong to the interval [0, 1]. Defining
b(r) = s¯(r)[c¯1(r) + 1.5%¯(r)] [1 + 10c¯2(r)]
− 2,
c(r) = 1− 1
c¯1(r) + 1.5%¯(r)
[ 1.1s¯(r)
1 + 10c¯2(r)
− 3%¯(r)− 0.01c¯1(r)
]
,
we verify, through numerical inspection, that the zero of equation (3.2) in the interval [0, 1]
without drugs and with cytostatic drugs only, is given as
X¯(r) = −b(r) +
√
b(r)2 − 4c(r)
2 , (3.3)
while the zero of equation (3.2) in the interval [0, 1] with cytotoxic drugs only, is given as
X¯(r) = −b(r)−
√
b(r)2 − 4c(r)
2 . (3.4)
Finally, we need b(r)2 − 4c(r) ≥ 0 otherwise (3.2) does not have a solution.
The curves X(T, r) in Fig. 7 obtained from the formula above show a good agreement with
the plots of the function n(T, r, x)/%(T, r) summarized in Fig. 1, Fig. 3 and Fig. 5.
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 10
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
r
X(T,r)
Figure 7: (Curves X(T, r) computed from equation (3.2)) Curves X(T, r) for C1,2(t) := 0
(solid line), C1(t) := 1 and C2(t) := 0 (dashed line), and C1(t) := 0 and C2(t) := 1 (dotted line).
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4 Study of optimized therapeutic protocols
In this section, we compare the efficacy of different schedules of drug delivery with the aim of
supporting the development of optimized therapeutic protocols. The effects of bang-bang infu-
sion of cytotoxic or cytostatic drugs are compared to the ones of constant supply in Subsection
4.1, while the same kind of comparison for cytotoxic and cytostatic drugs in combination is
provided in Subsection 4.2. Finally, the effects of therapeutic strategies that combine constant
delivery of cytotoxic drugs with bang-bang infusion of cytostatic drugs, and vice-versa, are in-
spected in Subsection 4.3. The infusion schemes (i.e., the boundary conditions C1,2(t)) in use
throughout this section are summarized by Fig. 8, where constants Ca,b,c,d model the delivered
doses and are defined, case by case, according to the scenario analyzed in each subsection and
in such a way that the total delivered dose (i.e.,
∫ T
0 [C1(t) + C2(t)] dt) remains always the same.
0 T/240
Ca
C1,2(t)
t
0 T/240
Cd
Cc
Cb
t
C1,2(t)
0 T/240
Ca
Cd
Cc
Cb
t
C1,2(t)
Figure 8: (Infusion schemes of cytotoxic and cytostatic drugs) Definitions of boundary
conditions C1,2(t). Left and center panels refer to constant and bang-bang infusion of cytotoxic
and/or cytostatic drugs, while right panel refers to the case where cytotoxic drugs are delivered
through a bang-bang infusion scheme while cytostatic drugs are constantly supplied, or vice-
versa. Fixed, dashed and dashed-dotted lines stand for three different instances of bang-bang
infusion, which are characterized by picks of different height/duration. The values of constants
Ca,b,c,d are defined, case by case, according to the situation considered in each subsection.
4.1 Constant vs bang-bang infusion of cytotoxic OR cytostatic drugs only
At first, we study the efficacy of therapeutic protocols relying on bang-bang delivery of cytotoxic
drugs only, and we compare the obtained results with the ones of constant infusion. We perform
simulations with C2(t) := 0 and C1(t) defined by the fixed line in the center panel in Fig. 8 with
Cb = 16, or the dashed line with Cc = 8 or the dashed-dotted line with Cd = 4. The obtained
results are compared to the outcomes of simulations developed with C2(t) := 0 and C1(t) defined
by the ∗-line in the left panel in Fig. 8 with Ca = 2.
Constant infusion of cytotoxic drugs leads to a temporary reduction of the cancer cell density,
which is then followed by a relapse caused by the emergence of resistance (see left panel (a) in
Fig. 10). On the other hand, the bang-bang infusion scheme with the same total dose slows
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down the selection of resistant cancer clones, but it is less effective in reducing the size of the
tumor cell population (see right panel (a) in Fig. 10).
Then, we develop the same kind of analysis for cytostatic drugs only. We perform simulations
with C1(t) := 0 and C2(t) defined as the ∗-line in the left panel in Fig. 8 with Ca = 2, or the
fixed line in the center panel in Fig. 8 with Cb = 16, or the dashed line with Cc = 8 or the
dashed-dotted line with Cd = 4.
As we already know from Section 3, constant infusion of cytostatic drugs tends to slow down
the evolution toward total sensitivity (i.e., the selection of high proliferative potentials) by com-
parison with the case without drugs (see left panel (b) in Fig. 10 and compare it with Fig. 9).
On the other hand, the dynamics of cancer cells under bang-bang delivery of cytostatic drugs
is qualitatively the same as the one observed in the absence of therapies (see right panel (b) in
Fig. 10 and compare it with Fig. 9).
In conclusion to this section, we notice that constant infusion of cytotoxic drugs leads to a
temporary reduction of the cancer cell density, while bang-bang delivery tends to slow down the
evolution toward total resistance. On the other hand, bang-bang infusion of cytostatic drugs
weakly affects the dynamics of cancer cells by comparison with the case without therapies. With
the doses used in our tests, neither constant nor bang-bang infusion of cytotoxic/cytostatic drugs
only allows a complete eradication of cancer cells.
4.2 Constant vs bang-bang infusion of cytotoxic AND cytostatic drugs
This subsection aims at making a comparison between the therapeutic effects of constant and
bang-bang delivery of cytotoxic and cytostatic drugs in combination. Therefore, we perform
simulations with C1,2(t) defined as the ∗-line in the left panel in Fig. 8 with Ca = 1 or the fixed
line in the center panel in the same figure with Cb = 8, or the dashed line with Cc = 4 or the
dashed-dotted line with Cd = 2.
While bang-bang infusion slows down the evolution toward total sensitivity which is observed
in the absence of therapeutic agents (see right panel in Fig. 11 and compare it with Fig. 9), the
constant infusion scheme at hand pushes cancer cells toward extinction (see left panel in Fig. 11).
This is consistent with experimental observations suggesting that combination therapies can be
more effective [10, 24, 27, 31] and leads us to conclude that, keeping equal the total delivered
dose of drugs, if cytotoxic and cytostatic drugs are used in combination, protocols relying on
simultaneous bang-bang infusion can be less effective than protocols relying on simultaneous
constant infusion.
It is worth noting that the total amount of delivered drugs is here the same as the ones consid-
ered in Subsection 4.1. Therefore, in agreement with the conclusions drawn in [15], these results
also suggest that looking for protocols based on different therapeutic agents in combination is a
more effective strategy for fighting cancer rather than using high drug doses.
In conclusion to this section, we observe that effective anti-cancer treatments can be designed
by making use of proper combinations between cytotoxic and cytostatic drugs. If these drugs are
delivered together, constant supply is more effective than bang-bang infusion and can favor the
total eradication of cancer cells.
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4.3 Mixed constant/bang-bang infusions of cytotoxic AND cytostatic drugs
Finally, using the two types of drugs at hand in combination, we test the effects of delivery
schedules relying on constant infusion of cytotoxic drugs and bang-bang infusion of cytostatic
drugs, and vice-versa. Therefore, we perform simulations with C1,2(t) as in the right panel in
Fig. 8. We set C1(t) := Ca = 1 and define C2(t) as the fixed line with Cb = 8 (or the dashed
line with Cc = 4, or the dashed-dotted line with Cd = 2), and vice-versa.
Bang-bang infusion of cytostatic drugs and constant infusion of cytotoxic drugs causes a
temporary reduction of the cancer cell density (see left panel in Fig. 12). On the other hand, in
good qualitative agreement with experimental observations [2], therapeutic protocols relying on
bang-bang infusion of cytotoxic drugs and constant delivery of cytostatic drugs can keep cancer
cells close to extinction (see right panel in Fig. 12), although a detectable number of cancer cells
survives within the population.
These results, together with the ones presented in Subsection 4.2, support the idea that more
effective therapeutic protocols can be designed by using cytotoxic and cytostatic drugs in com-
bination, with constant delivery for both drugs, or bang-bang infusion for cytotoxic drugs and
constant infusion for cytostatic drugs. Moreover, if the delivered doses of each class of thera-
peutic agents are kept the same, protocols that make use of constant delivery for both classes of
anti-cancer agents make possible a complete eradication of cancer cells, while protocols relying
on bang-bang infusion of cytotoxic drugs and constant infusion of cytostatic drugs make only
possible a good control on tumor size.
In conclusion to this section, we notice that therapeutic protocols relying on bang-bang infusion
of cytotoxic drugs - constant delivery of cytostatic drugs are more effective than therapeutic
protocols based on bang-bang infusion of cytostatic drugs - constant delivery of cytotoxic drugs.
The former allow a good control on tumor size by keeping cancer cells close to extinction, while
the latter make only possible a temporary reduction of the cancer cell density and leave space for
tumor relapse, which arises due to the emergence of resistance.
Figure 9: (Cell dynamics without therapies) Plot of
∫ 1
0 n(t, r, x)dr for C1,2(t) := 0. In
agreement with the results presented in Section 3, cells characterized by a low expression level
of resistance to cytotoxic therapies (i.e., a strong proliferative potential) are selected and intra-
tumor heterogeneity is high. To be compared with Fig. 10 and Fig. 11.
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(a)
(b)
Figure 10: (Constant vs bang-bang infusion of cytotoxic OR cytostatic drugs)
(a) Constant vs bang-bang infusion of cytotoxic drugs only. Plots of
∫ 1
0 n(t, r, x)dr for
C2(t) := 0 and C1(t) defined as the ∗-line in the left panel in Fig. 8 with Ca = 2 (left panel)
or the fixed line in the center panel in the same figure with Cb = 16 (right panel). Analogous
results hold for bang-bang regimes illustrated in Fig. 8 by the dashed line with Cc = 8 and the
dashed-dotted line with Cd = 4 (data not shown). Constant infusion of cytotoxic drugs leads to
a temporary reduction of the cancer cell density, while bang-bang delivery tends to slow down
the evolution toward total resistance.
(b) Constant vs bang-bang infusion of cytostatic drugs only. Plots of
∫ 1
0 n(t, r, x)dr for
C1(t) := 0 and C2(t) defined as the ∗-line in the left panel in Fig. 8 with Ca = 2 (left panel)
or the fixed line in the center panel in the same figure with Cb = 16 (right panel). Analogous
results hold for bang-bang regimes illustrated in Fig. 8 by the dashed line with Cc = 8 and the
dashed-dotted line with Cd = 4 (data not shown). Constant infusion of cytostatic drugs slows
down the selection of highly proliferative cancer clones, while bang-bang infusion weakly affects
the dynamics of cancer cells with respect to the case without therapies.
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Figure 11: (Constant vs bang-bang infusion of cytotoxic AND cytostatic drugs) Plots
of
∫ 1
0 n(t, r, x)dr for C1,2(t) defined as the ∗-line in the left panel in Fig. 8 with Ca = 1 (left panel)
or the fixed line in the center panel of the same figure with Cb = 8 (right panel). Analogous
results hold for bang-bang regimes illustrated in Fig. 8 by the dashed line with Cc = 4 and the
dashed-dotted line with Cd = 2 (data not shown). While bang-bang infusion slows down the
evolution toward total sensitivity which is observed in the absence of therapeutic agents, the
constant infusion scheme pushes cancer cells toward extinction.
Figure 12: (Mixed constant/bang-bang infusions of cytotoxic AND cytostatic drugs)
Plots of
∫ 1
0 n(t, r, x)dr for C1,2(t) as in the right panel in Fig. 8 with C1(t) := Ca = 1 and C2(t)
defined as the fixed line with Cb = 8 (left panel), or vice-versa (right panel). Analogous results
hold for bang-bang regimes illustrated in Fig. 8 by the dashed line with Cc = 4 and the dashed-
dotted line with Cd = 2 (data not shown). Bang-bang infusion of cytostatic drugs together with
constant infusion of cytotoxic drugs causes a temporary reduction of the cancer cell density.
On the other hand, bang-bang infusion of cytotoxic drugs together with constant delivery of
cytostatic drugs can keep cancer cells close to extinction, although a detectable number of
cancer cells survives within the population.
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5 Conclusions and perspectives
Departing from theories derived in other contexts of population biology and Darwinian evolution,
we have developed a structured population model for the dynamics of cancer cells exposed to
cytotoxic and cytostatic drugs. Relying on the assumption that cells are organized in a radially
symmetric spheroid, the present model takes explicitly into account the dynamics of resources
and anti-cancer drugs, which define the cellular environment. In the present model, space
structure together with diffusion of nutrients and therapeutic agents are the key ingredients
providing the basis for intra-tumor heterogeneity (i.e., the simultaneous selection of several
levels of resistance/proliferative potential within the cancer cell population).
5.1 Study of cell environmental adaptation and phenotypic heterogeneity
In the framework of this model, we have first made use of numerical simulations to analyze the
evolution of phenotypic heterogeneity and the emergence of resistance to therapies (see Section
3), and we have reached the following conclusions:
• Phenotypic heterogeneity within solid tumor aggregates might be explained, at least par-
tially, by cell adaptation to local conditions. In fact, cells characterized by different levels of
proliferative potential and resistance to therapies are selected depending on space position, in
relation with the distributions of resources and anti-cancer drugs.
• Cytostatic drugs tend to slow down tumor evolution, while cytotoxic drugs favor the selection
of highly resistant cancer clones and cause a decrease in the heterogeneity with respect to the
resistance trait. In the framework of our model, this is not in contradiction with the Gause
competitive exclusion principle.
5.2 Study of optimized therapeutic protocols
As a second step, we have tested, in silico, the capability of different therapeutic protocols to
effectively contrast cancer progression. The cases of constant infusion, bang-bang delivery and
mixed constant - bang-bang infusion of the anti-cancer drugs at hand have been considered (see
Section 4). The results we have obtained lead us to the following conclusions:
• Looking for combination therapies relying on cytotoxic and cytostatic drugs is a more ef-
fective strategy for fighting cancer rather than using high doses of cytotoxic or cytostatic drugs
only.
• If cytotoxic and cytostatic drugs are delivered together, constant supply is more effective than
bang-bang infusion, or mixed constant and bang-bang infusion, since it can actually push cancer
cells toward extinction.
• Therapeutic protocols relying on bang-bang infusion of cytotoxic drugs and constant delivery
of cytostatic drugs favor a good control on tumor size and they are more effective than therapeu-
tic protocols based on bang-bang infusion of cytostatic drugs and constant delivery of cytotoxic
drugs. Since constant supplies might be excluded in practice for toxicity reasons, bang-bang
cytotoxic associated with constant cytostatic infusion might turn out to be optimal.
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5.3 Perspectives
Future researches will be addressed to extend the present model in order to include the dynamics
of healthy cells and studying how to handle unwanted toxic side effects related to the delivery of
anti-cancer agents in healthy cell populations. In view of this, a possible research direction is to
approach the toxicity problem at stake as an optimal control problem, where the systemic cost
for human body related to cancer growth and therapy infusion has to be minimized under the
constraint that a minimal density of healthy cells should be preserved inside the system. In the
same way, in view of adaptive therapy [4], preserving a minimal proportion of cancer cells under
a sensitivity threshold x ≤ xs (to be tuned) is another possible constraint to be represented in
an optimal control problem. This general direction of research, using optimal control settings,
clearly aims at therapeutic optimization in the clinic of cancers.
From a modeling point of view, the present theoretical study, that has taken into account
(additionally to the space variable r) only one drug resistance trait (x) for two different classes
of anticancer drugs should also be completed in the future by further work involving a multidi-
mensional structure variable x including different resistant phenotypes to different drugs, and
possibly other phenotypes related to epithelial-to-mesenchymal transition, glycolytic metabolism
phenotype, dormancy, etc. as cell subpopulations less accessible to treatment than the classical
forms of in situ proliferating epithelial solid tumors.
From a more biological point of view, understanding what are the cell population characters
(genetically or epigenetically determined?) aggregated in this structure variable (r, x) standing
for spatial heterogeneity and quantitated drug resistance, and how it can be related in experi-
mental measurements with gene expression or epigenetic enzyme activity, is a big challenge that
must be faced in transdisciplinary studies gathering mathematicians and biologists. We know
from Luria and Delbrück’s princeps experiment [17] that some drug resistance, due to stochas-
tic genetic mutations in cell populations, occurring prior to drug exposure, is likely to exist
in cancer cell populations, all the more so as genome instability is a common feature of these
cells. Finding out what are the respective parts played in drug resistance by purely stochastic
processes [9] on the one hand, and by more Lamarckian phenomena resulting from adaptation
of the cells surviving a massive drug insult, involving epigenetic mechanisms in response [23],
and thus justifying the use of deterministic models, is another challenge that we intend to tackle
in forthcoming studies.
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